Evidence map›Paper›PMID 38302683›Full record

ArticleScientific reports2024

A novel preliminary metabolomic panel for IHD diagnostics and pathogenesis.

S S Markin, E A Ponomarenko, Yu A Romashova, T O Pleshakova, S V Ivanov, F N Bedretdinov, S L Konstantinov, A A Nizov, A G Koledinskii, A I Girivenko and 6 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
2.1field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 4 institutions in 1 country.

S S MarkinInstitute of Biomedical Chemistry, Moscow, Russia, 119121. phospholipovit@ibmc.msk.ru.
E A PonomarenkoInstitute of Biomedical Chemistry, Moscow, Russia, 119121.
Yu A RomashovaInstitute of Biomedical Chemistry, Moscow, Russia, 119121.
T O PleshakovaInstitute of Biomedical Chemistry, Moscow, Russia, 119121.
S V IvanovInstitute of Biomedical Chemistry, Moscow, Russia, 119121.
F N BedretdinovInstitute of Biomedical Chemistry, Moscow, Russia, 119121.
S L KonstantinovBelgorod Regional Clinical Hospital of St. Joseph, Belgorod, Russia, 308007.
A A NizovI.P. Pavlov Ryazan State Medical University, Ryazan, Russia, 390026.
A G KoledinskiiPeoples' Friendship University of Russia, Moscow, Russia, 117198.
A I GirivenkoI.P. Pavlov Ryazan State Medical University, Ryazan, Russia, 390026.
K M ShestakovaLaboratory of Pharmacokinetics and Metabolomic Analysis, Institute of Translational Medicine and Biotechnology, I.M. Sechenov First Moscow Medical University (Sechenov University), Moscow, Russia, 119435.
P A MarkinLaboratory of Pharmacokinetics and Metabolomic Analysis, Institute of Translational Medicine and Biotechnology, I.M. Sechenov First Moscow Medical University (Sechenov University), Moscow, Russia, 119435.
N E MoskalevaWorld-Class Research Center Digital Biodesign and Personalized Healthcare, I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia, 119435.
M V KozhevnikovaHospital Therapy No1, Department of the N.V. Sklifosovsky Institute of Clinical Medicine, I.M. Sechenov First Moscow Medical University (Sechenov University), Moscow, Russia, 119435.
Zh Yu ChefranovaBelgorod Regional Clinical Hospital of St. Joseph, Belgorod, Russia, 308007.
S A AppolonovaLaboratory of Pharmacokinetics and Metabolomic Analysis, Institute of Translational Medicine and Biotechnology, I.M. Sechenov First Moscow Medical University (Sechenov University), Moscow, Russia, 119435.
Institute of Biomedical Chemistry · RUSechenov University · RURyazan State Medical University named after Academician I.P. Pavlov · RUPeoples' Friendship University of Russia · RU

Funding

Ministry of Science and Higher Education of the Russian Federation within the framework of state support for the creation and development of World-Class Research Centers 'Digital Biodesign and Personalized Healthcare' No 075-15-2022-305
6 · The paper itself

Abstract

Cardiovascular disease (CVD) represents one of the main causes of mortality worldwide and nearly a half of it is related to ischemic heart disease (IHD). The article represents a comprehensive study on the diagnostics of IHD through the targeted metabolomic profiling and machine learning techniques. A total of 112 subjects were enrolled in the study, consisting of 76 IHD patients and 36 non-CVD subjects. Metabolomic profiling was conducted, involving the quantitative analysis of 87 endogenous metabolites in plasma. A novel regression method of age-adjustment correction of metabolomics data was developed. We identified 36 significantly changed metabolites which included increased cystathionine and dimethylglycine and the decreased ADMA and arginine. Tryptophan catabolism pathways showed significant alterations with increased levels of serotonin, intermediates of the kynurenine pathway and decreased intermediates of indole pathway. Amino acid profiles indicated elevated branched-chain amino acids and increased amino acid ratios. Short-chain acylcarnitines were reduced, while long-chain acylcarnitines were elevated. Based on these metabolites data, machine learning algorithms: logistic regression, support vector machine, decision trees, random forest, and gradient boosting, were used for IHD diagnostic models. Random forest demonstrated the highest accuracy with an AUC of 0.98. The metabolites Norepinephrine; Xanthurenic acid; Anthranilic acid; Serotonin; C6-DC; C14-OH; C16; C16-OH; GSG; Phenylalanine and Methionine were found to be significant and may serve as a novel preliminary panel for IHD diagnostics. Further studies are needed to confirm these findings.

Indexed as

Cardiovascular DiseasesMyocardial IschemiaAmino AcidsAmino Acids, Branched-ChainHumansMetabolomicsSerotoninAmino AcidsAmino Acids, Branched-ChainSerotonin

Identifiers

PMID38302683
PMCPMC10834974
OpenAlexW4391437652

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.